表纸
市场调查报告书

AEterna Zentaris Inc.:产品平台分析

Aeterna Zentaris Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品编码 192446
出版日期 内容资讯 英文 53 Pages
订单完成后即时交付
价格
Back to Top
AEterna Zentaris Inc.:产品平台分析 Aeterna Zentaris Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日内容资讯: 英文 53 Pages
简介

AEterna Zentaris Inc.是开发癌症、内分泌障碍及感染疾病治疗药的后期医药品开发企业。

本报告提供AEterna Zentaris Inc.的治疗药开发平台现况及各开发阶段比较分析,提供您药物标的,作用机制,给药途径,各分子类型的治疗药评估,最新的企业新闻和发表,后期阶段及中止的计划等相关资讯。

AEterna Zentaris Inc.的基本资料

  • AEterna Zentaris Inc.概要
  • 主要资讯
  • 企业资料

AEterna Zentaris Inc.:R&D概要

  • 主要的治疗范围

AEterna Zentaris Inc.:开发平台评估

  • 各开发阶段的开发中产品
  • 单剂产品

AEterna Zentaris Inc.:开发中产品概况

  • 最后阶段的开发中产品
    • 申请驳回的/撤消产品/联合治疗模式
    • 第三阶段的产品/联合治疗模式
  • 临床实验阶段的开发中产品
    • 第二阶段的产品/联合治疗模式
    • 第一阶段的产品/联合治疗模式
  • 初期阶段的开发中产品
  • IND/CTA 所申请的产品/联合治疗模式
    • 前临床阶段的产品/联合治疗模式
    • 药物研发中的产品/联合治疗模式

AEterna Zentaris Inc.:药物简介

  • mmacimorelin acetate
  • zoptarelin doxorubicin
  • ozarelix
  • perifosine
  • AEZS-120
  • AEZS-124
  • AEZS-125
  • AEZS-126
  • AEZS-127
  • AEZS-129
  • AEZS-134
  • AEZS-136
  • AEZS-137
  • AEZS-138
  • AN-207
  • Small Molecules for Undisclosed Indication
  • Small Molecules to Inhibit ERK2 and Aurora B Kinase for Cancer

AEterna Zentaris Inc.:开发平台分析

  • 标的别
  • 各给药途径
  • 各分子类型
  • 各作用机制

AEterna Zentaris Inc.:最近的开发平台趋势

AEterna Zentaris Inc.:暂停中的计划

AEterna Zentaris Inc.:开发中止的开发中产品

  • 开发中止的开发中产品简介
    • AEZS-115
    • AEZS-123
    • AEZS-131
    • AEZS-132
    • AN-215
    • AN-238
    • perifosine
    • teverelix

AEterna Zentaris Inc.:企业发表

AEterna Zentaris Inc.:总公司和子公司的所在地

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC08081CDB

Summary:

Global Markets Direct's, 'Aeterna Zentaris Inc. - Product Pipeline Review - 2016', provides an overview of the Aeterna Zentaris Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Aeterna Zentaris Inc.
  • The report provides overview of Aeterna Zentaris Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Aeterna Zentaris Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Aeterna Zentaris Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Aeterna Zentaris Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Aeterna Zentaris Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aeterna Zentaris Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Aeterna Zentaris Inc. Snapshot
    • Aeterna Zentaris Inc. Overview
    • Key Information
    • Key Facts
  • Aeterna Zentaris Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Aeterna Zentaris Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Aeterna Zentaris Inc. - Pipeline Products Glance
    • Aeterna Zentaris Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Aeterna Zentaris Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Aeterna Zentaris Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Aeterna Zentaris Inc. - Drug Profiles
    • zoptarelin doxorubicin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • macimorelin acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozarelix
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-124
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-126
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-138
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEZS-140
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aeterna Zentaris Inc. - Pipeline Analysis
    • Aeterna Zentaris Inc. - Pipeline Products by Target
    • Aeterna Zentaris Inc. - Pipeline Products by Route of Administration
    • Aeterna Zentaris Inc. - Pipeline Products by Molecule Type
    • Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action
  • Aeterna Zentaris Inc. - Recent Pipeline Updates
  • Aeterna Zentaris Inc. - Dormant Projects
  • Aeterna Zentaris Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AEZS-115
      • AEZS-123
      • AEZS-131
      • AEZS-132
      • AN-215
      • AN-238
      • perifosine
      • teverelix
  • Aeterna Zentaris Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Aeterna Zentaris Inc., Key Information
  • Aeterna Zentaris Inc., Key Facts
  • Aeterna Zentaris Inc. - Pipeline by Indication, 2016
  • Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016
  • Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016
  • Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016
  • Aeterna Zentaris Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Aeterna Zentaris Inc. - Phase III, 2016
  • Aeterna Zentaris Inc. - Phase II, 2016
  • Aeterna Zentaris Inc. - IND/CTA Filed, 2016
  • Aeterna Zentaris Inc. - Preclinical, 2016
  • Aeterna Zentaris Inc. - Discovery, 2016
  • Aeterna Zentaris Inc. - Pipeline by Target, 2016
  • Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016
  • Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016
  • Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action, 2016
  • Aeterna Zentaris Inc. - Recent Pipeline Updates, 2016
  • Aeterna Zentaris Inc. - Dormant Developmental Projects,2016
  • Aeterna Zentaris Inc. - Discontinued Pipeline Products, 2016
  • Aeterna Zentaris Inc., Subsidiaries

List of Figures

  • Aeterna Zentaris Inc. - Pipeline by Top 10 Indication, 2016
  • Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016
  • Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016
  • Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016
  • Aeterna Zentaris Inc. - Pipeline by Top 10 Target, 2016
  • Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016
  • Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016
  • Aeterna Zentaris Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top